Show simple item record

dc.contributor.authorSchurink-van 't Klooster, Tessa M
dc.contributor.authorDonken, Robine
dc.contributor.authorSchepp, Rutger M
dc.contributor.authorvan der Klis, Fiona R M
dc.contributor.authorde Melker, Hester E
dc.date.accessioned2019-02-12T11:15:04Z
dc.date.available2019-02-12T11:15:04Z
dc.date.issued2018-11-26
dc.identifier.issn1873-2518
dc.identifier.pmid30377068
dc.identifier.doi10.1016/j.vaccine.2018.10.018
dc.identifier.urihttp://hdl.handle.net/10029/622717
dc.description.abstractIn this cohort study, we examined antibody levels and avidity after a two-dose schedule (0, 6 months) of the bivalent HPV-vaccine in girls routinely vaccinated in the Dutch HPV-vaccination program, up to 2 years following vaccination. A blood sample at 7, 12 and 24 months after the first dose and questionnaire data were collected (n = 56). HPV type-specific antibody concentrations (lU/ml) against seven types (HPV16/18/31/33/45/52/58) were assessed using a validated virus-like particles (VLP) multiplex immunoassay. Avidity was tested using a modification of this assay. Seropositivity for vaccine types HPV 16 and 18 was 100% up to month 24, but declined for HPV-types 31/33/45/52/58, although not statistically significant for HPV45. All Geometric Mean Concentrations (GMCs) declined by months 12 and 24, but remained high for HPV16/18. Between month 7 and 12, GMCs declined more for other types. High avidity antibodies were induced up to 24 months for vaccine types (75%, 76-78% and 81-82% at months 7, 12 and 24, respectively), but for other types antibody avidity was 16-29% at month 7, 20-32% at month 12 and 19-32% at month 24. GMCs declined over time for HPV-types 16/18/31/33/45/52/58, but remained high for vaccine-types HPV16/18 up to 24 months of follow-up. Antibody avidity was >75% for vaccine types but <35% for other HPV-types. Further follow-up of this cohort will provide insight into antibody and avidity kinetics over time.en_US
dc.language.isoenen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.subjectAntibody concentrationen_US
dc.subjectAvidityen_US
dc.subjectGMCen_US
dc.subjectHPVen_US
dc.subjectTwo-dose scheduleen_US
dc.subjectVaccineen_US
dc.titlePersistence of immune response following bivalent HPV vaccination: A follow-up study among girls routinely vaccinated with a two-dose schedule.en_US
dc.typeArticleen_US
dc.identifier.journalVaccine 2018; 36(49):7580-7en_US
dc.source.journaltitleVaccine
refterms.dateFOA2019-02-12T11:15:04Z


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States